Protalix BioTherapeutics, Inc.PLXNYSE
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year earnings per share growth rate
Latest
1328.57%
↑ 273% above average
Average (39q)
356.35%
Historical baseline
Range
High:18060.69%
Low:-2536.26%
CAGR
-6.5%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | 1328.57% |
| Q2 2025 | 104.45% |
| Q1 2025 | -153.03% |
| Q4 2024 | 102.27% |
| Q3 2024 | 246.67% |
| Q2 2024 | 50.00% |
| Q1 2024 | 27.54% |
| Q4 2023 | -223.44% |
| Q3 2023 | -108.83% |
| Q2 2023 | 680.00% |
| Q1 2023 | 31.32% |
| Q4 2022 | -4.00% |
| Q3 2022 | 36.36% |
| Q2 2022 | -120.00% |
| Q1 2022 | 66.67% |
| Q4 2021 | -62.69% |
| Q3 2021 | 63.12% |
| Q2 2021 | -78.57% |
| Q1 2021 | -1257.02% |
| Q4 2020 | 108.64% |
| Q3 2020 | -7.69% |
| Q2 2020 | -230.00% |
| Q1 2020 | 498.80% |
| Q4 2019 | 106.96% |
| Q3 2019 | 53.85% |
| Q2 2019 | -6.12% |
| Q1 2019 | -174.24% |
| Q4 2018 | 265.00% |
| Q3 2018 | 33.33% |
| Q2 2018 | -20.00% |
| Q1 2018 | 53.70% |
| Q4 2017 | -25.58% |
| Q3 2017 | -2536.26% |
| Q2 2017 | 100.74% |
| Q1 2017 | -2161.90% |
| Q4 2016 | 70.00% |
| Q3 2016 | -536.36% |
| Q2 2016 | -27.61% |
| Q1 2016 | -101.18% |
| Q4 2015 | 18060.69% |